Pazopanib dose hunt in frail seniors halted early
NCT ID NCT01642017
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated early, so the full planned enrollment of 30 patients was not reached.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pazopanib (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this could help doctors find a safer dose of pazopanib for frail elderly patients with advanced cancer, potentially offering a treatment option where few exist.
What could go wrong
This is a very early, small phase 1 trial that was terminated early, so results are limited. The drug may still cause significant side effects, and it is not a cure—patients take it until the disease gets worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre François BACLESSE
Caen, 14076, France
-
Centre Léon BERARD
Lyon, 69008, France
-
Hôpital Saint André
Bordeaux, 33075, France
-
Institut Claudius REGAUD
Toulouse, 31052, France